2013
Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD. Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. PLOS ONE 2013, 8: e84173. PMID: 24367639, PMCID: PMC3867470, DOI: 10.1371/journal.pone.0084173.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioQuality-adjusted life monthsRoutine HIVHIV test acceptanceRoutine HIV screeningAge 43 yearsCells/μLSecondary HIV transmissionHigh-risk groupHigh-risk populationRoutine screening programQuality-adjusted survivalCost-effectiveness ratioCD4 countHIV screeningClinical outcomesHIV prevalenceHIV transmissionFrequent screeningClinical impactNational HIVScreening programHigh incidenceHIV
2011
Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department
Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, Katz JN, Losina E. Resource Utilization and Cost-Effectiveness of Counselor- vs. Provider-Based Rapid Point-of-Care HIV Screening in the Emergency Department. PLOS ONE 2011, 6: e25575. PMID: 22022415, PMCID: PMC3192047, DOI: 10.1371/journal.pone.0025575.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioUndiagnosed HIV prevalenceEmergency department settingCost-effectiveness ratioHIV prevalenceDepartment settingScreening modalityRandomized clinical trialsResource utilization dataRoutine HIVHIV screeningHIV counselorsEmergency departmentScreening servicesClinical trialsCapacity of providersScreening programED staffHIVTest offerLife yearsUtilization dataRapid pointPrevalence
2010
Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC
Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, Seage GR, Freedberg KA, Investigators F. Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. Clinical Infectious Diseases 2010, 51: 392-400. PMID: 20617921, PMCID: PMC2906630, DOI: 10.1086/655130.Peer-Reviewed Original ResearchConceptsHIV RNA levelsAntiretroviral therapyLife expectancyAdministration of ARTHuman immunodeficiency virus (HIV) epidemicART initiation strategiesHIV case detectionRNA levelsUndiagnosed HIV prevalenceCells/microLEarly case identificationInitial mean ageRegular screening programsHIV screeningHIV testAnnual incidenceAnnual screeningHIV prevalenceHIV transmissionHIV strategiesMean ageHIV epidemicCase detectionScreening programART efficacy
2005
Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral
Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral. Medical Decision Making 2005, 25: 321-329. PMID: 15951459, DOI: 10.1177/0272989x05276955.Peer-Reviewed Original ResearchMeSH KeywordsAIDS SerodiagnosisComputer SimulationContinuity of Patient CareCost-Benefit AnalysisCounselingDecision Support TechniquesHIV InfectionsHumansInvestmentsMass ScreeningModels, StatisticalPatient Acceptance of Health CarePrevalenceProbabilityQuality-Adjusted Life YearsReferral and ConsultationResource AllocationSensitivity and SpecificityUnited StatesConceptsCost-effectiveness ratioScreening programUndiagnosed HIV prevalenceHealth screening programHIV testing servicesHIV testingHIV counselingHIV prevalenceLimited screening resourcesClinical impactAppropriate careQALYTesting pathwayTesting servicesScreening resourcesPathway outcomesOptimal targetingCarePathwayEarly stagesHIVReferralAdditional peopleFollowLater stagesRoutine human immunodeficiency virus testing: An economic evaluation of current guidelines
Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. The American Journal Of Medicine 2005, 118: 292-300. PMID: 15745728, DOI: 10.1016/j.amjmed.2004.07.055.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioHIV prevalenceCurrent guidelinesHuman immunodeficiency virus (HIV) counselingMean quality-adjusted life expectancyHIV Screening ProgramQuality-adjusted life expectancyLife-sustaining careOverall participation rateCost-effectiveness analysisUndiagnosed infectionHIV screeningHIV counselingClinical effectsReferral guidelinesPrevention guidelinesInfected patientsScreening programDisease controlPrevalenceU.S. hospitalsScreening thresholdLife expectancyHIVPatients